Search

Displaying results 2371 - 2380 of 2959 in total
  1. Drug

    Manganese citrate

    go.drugbank.com/drugs/DB14495
    Approved

    Mixtures: Collag-EN
  2. Drug

    Cysteine

    go.drugbank.com/drugs/DB00151
    ApprovedInvestigationalNutraceutical

    A thiol-containing non-essential amino acid that is oxidized to form cystine.

    Mixtures: Numeta G 13 % E Emulsion zur Infusion, Numeta G 16 % E Emulsion zur Infusion
  3. Drug

    Chlorophyll B

    go.drugbank.com/drugs/DB04506
    Experimental

    (From Dorland, 27th ed)

  4. Drug

    Mirfentanil

    go.drugbank.com/drugs/DB09175
    Experimental

    Mirfentanil is a derivative of fentanyl that presents high selectivity for the mu opioid receptor.

  5. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule

  6. Drug

    Methotrexate

    go.drugbank.com/drugs/DB00563
    ApprovedInvestigational

    [L7180] Methotrexate was granted FDA approval on 7 December 1953.[L7198]

    Products: NORDIMET 10MG ILO I E FER, NORDIMET 15MG ILO I E FER
  7. Drug

    Bromocriptine

    go.drugbank.com/drugs/DB01200
    ApprovedInvestigationalWithdrawn

    In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use.

    Products: Nu-bromocriptine
  8. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2.

  9. Drug

    Givinostat

    go.drugbank.com/drugs/DB12645
    ApprovedInvestigational

    [L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD).

  10. Drug

    Ceftolozane

    go.drugbank.com/drugs/DB09050
    ApprovedInvestigational

    [L6685] It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections.